Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
Compounds significantly restored β-Gal function and reduced intracellular toxic substrates in model of GM1 gangliosidosis
Results published in PLOS ONE in collaboration with Institute for Research in Biomedicine
Related news for (GANX)
- Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
- 24/7 Market News Snapshot 06 October, 2025 – Gain Therapeutics, Inc. Common Stock (NASDAQ:GANX)
- MoBot alert highlights: NASDAQ: RUN, NASDAQ: CASI, NYSE: UP, NASDAQ: IOBT, NASDAQ: GANX (08/15/25 02:00 PM)
- Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
- Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
